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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (overview). The objectives are as follows:
To provide an overview of the therapeutic eMicacy of pharmacological therapies for fibromyalgia (fibromyalgia syndrome) in adults, and
to report on adverse events associated with their use. The major comparison of interest will be with placebo.
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B A C K G R O U N D
This protocol is based on a template for Cochrane Reviews
of medicines used to relieve pain associated with fibromyalgia
syndrome (FMS). The aim is for Cochrane Reviews to use the same
or similar methods, based on new criteria for what constitutes
reliable evidence in chronic pain (Moore 2010a; Appendix 1), and in
FMS in particular (Arnold 2012).
Description of the condition
FMS has been defined traditionally as widespread pain that lasts
for longer than three months, with pain on palpation at 11 or more
of 18 specified tender points (Wolfe 1990). For the International
Classification of Diseases ICD-11 of the World Health Organisation
WHO, FMS was relocated from its legacy ICD-10 chapter location
to a new category block in the Symptoms, signs chapter, as an 
inclusion term under Chronic Primary Pain (CWP). It is currently
coded as an inclusion term under CWP (Code MG30.01). The WHO
uses the term fibromyalgia syndrome and not the term fibromyalgia
(FM). FMS is defined as a form of CWP (pain in at least 4 of 5
body regions or in at least 3 or 4 body quadrants) associated with
sleep disorders, cognitive dysfunction, and somatic symptoms. The
symptoms have been present at a similar level for at least three
months and are not better accounted for by another diagnosis
(Nicholas 2019; World Health Organization 2020).
For a clinical diagnosis, the ACR 1990 classification criteria
(Wolfe 1990), the ACR 2010 preliminary diagnostic criteria (Wolfe
2010), the 2011 diagnostic criteria (Wolfe 2011), the 2016
diagnostic criteria (Wolfe 2016), the ACTTION-APS Pain Taxonomy
(AAPT) diagnostic criteria (Analgesic, Anesthetic, and Addiction
Clinical Trial Translations Innovations Opportunities and Networks
(ACTTION)) public-private partnership with the U.S. Food and Drug
Administration (FDA), and the American Pain Society (APS) are
used (Arnold 2019). Diagnosis is established by a history of the
key symptoms and the exclusion of somatic diseases suMiciently
explaining the key symptoms (Häuser 2015). FMS symptoms
can be assessed by patient's self-report, via the fibromyalgia
criteria and severity scales for clinical and epidemiological studies,
a modification of the ACR Preliminary Diagnostic Criteria for
Fibromyalgia, the so-called Fibromyalgia Symptom Questionnaire
(Wolfe 2011). The severity of the AAPT criteria of sleep problems
or fatigue, or both, are assessed by the physician (Arnold 2019).
Clinical guidelines have suggested a clinical work-up with detailed
history taking of a FMS-like symptom cluster, complete physical
examination and some laboratory tests to screen for somatic
diseases which can fully explain FMS-like symptoms and/or might
contribute to CWP and fatigue (Fitzcharles 2013, Häuser 2015,
Arnold 2019).
A definite aetiology (cause) of this syndrome remains unknown.
A model of interacting biological and psychosocial variables in
the predisposition, triggering, and development of the chronicity
of fibromyalgia symptoms has been suggested (Üceyler 2017). A
systematic review of prospective cohort studies in the general
population on risk factors of CWP and FMS identified various
childhood diMiculties (e.g. physical and sexual abuse), female
sex (except with pre-existing medical disorders), older/middle
age, smoking, high body mass index, alcohol abstinence, and
pre-existing medical disorders in adulthood. The strongest
associations were with sleep disorders, headaches and other
pains, depression, and illness behaviour (Creed 2020). Genome-
wide association studies investigated genes potentially involved
in FMS pathogenesis highlighting that genetic factors are possibly
responsible for up to 50% of the disease susceptibility. Potential
candidate genes found associated to FMS are SLC64A4, TRPV2,
MYT1L, and NRXN3 (D'Agnelli 2019). Triggering of fibromyalgia
symptoms in predisposed persons by inflammatory rheumatic
diseases and psychosocial stress (e.g. workplace and family
conflicts) is largely ensured whereas the evidence on physical
stress (e.g. infections, surgery, accidents) as triggering factors is
inconclusive (Häuser 2015).
Several factors are associated with the pathophysiology (functional
changes associated with or resulting from disease) of fibromyalgia,
but the precise relationship to symptoms of the disorder is
unclear (Üceyler 2017). The best established pathophysiological
features are those of central sensitisation; that is, augmented
pain and sensory processing in the central nervous system
(CNS), with increased functional connectivity to pro-nociceptive
brain regions and decreased connectivity to antinociceptive
regions, and accompanying changes in CNS neurotransmitters
as well as the size and shape of brain regions (Cagnie 2017;
Clauw 2014). Other findings include sympathetic nervous system
dysfunction (Martínez-Martínez 2014), increased pro-inflammatory
and reduced anti-inflammatory cytokine profiles (produced by cells
involved in inflammation) (Üceyler 2011), and small fibre pathology
(Üceyler 2017).
Fibromyalgia is common. A review indicated a global mean
prevalence of 2.7% (range 0.4% to 9.3%), and a mean in the
Americas of 3.1%, in Europe of 2.5%, and in Asia of 1.7% (Queiroz
2013). Fibromyalgia is more common in women, with a female to
male ratio of 3:1 (4.2%:1.4%). Estimates of prevalence in specific
populations vary greatly, but have been reported to be as high as
9% in female textile workers in Turkey and 10% in metalworkers in
Brazil (59% in those with repetitive strain injury; Queiroz 2013). The
change in diagnostic criteria does not appear to have significantly
aMected estimates of prevalence (Wolfe 2013, Häuser 2021).
The clinical picture (symptoms, disability) of people meeting
FMS criteria is heterogenous. FMS can be associated with
mental disorders (mainly anxiety and depressive disorders) and
other chronic secondary pain syndromes such as inflammatory
rheumatic diseases and osteoarthritis (Fitzcharles 2018). Overlap
of FMS and various chronic primary pain syndromes is
prevalent, too. The U.S. Congress and National Institutes of
Health has recommended to use the term Chronic Overlapping
Pain Conditions (COPCs) for pain conditions which involve
many organ systems: vulvodynia, temporomandibular disorders,
myalgic encephalomyelitis/chronic fatigue syndrome, irritable
bowel syndrome, interstitial cystitis/painful bladder syndrome,
endometriosis, chronic tension-type headache, chronic migraine
headache and chronic low back pain (Maixner 2016). Prevalence
rates for FMS in these various conditions range from 20% to
65% (Fitzcharles 2018). Mild, moderate and severe forms of FMS
can be diMerentiated (Häuser 2018). Symptom severity and the
extent of disability of people with FMS is associated with somatic
and psychological comorbidities (Häuser 2015), and occupational
characteristics such as physically demanding jobs and work tasks
(Palstam 2017). Most people with FMS report high disability levels
and poor quality of life, along with extensive use of medical care
(Häuser 2015). There is oTen significant disability, with moderate
or severe pain experienced for many years (Bennett 2007).
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Fibromyalgia symptoms are known to be diMicult to treat
eMectively, with only a minority of individuals experiencing a
clinically-relevant benefit from any one intervention. A range of
non-pharmacological and pharmacological interventions is or may
be used, depending on the particular clinical situation and licensed
indications of medicines.
A stepwise and graduated approach depending on the key
symptoms and the extent of disability is recommended by recent
clinical guidelines (Macfarlane 2017; Petzke 2017). Guidelines
recommend starting with education, defining realistic goals
of therapy (improvement of daily functioning), and non-
pharmacological therapies such as exercise and psychological
therapies though evidence of major eMectiveness of these
is limited (Geneen 2017; Williams 2020). A multidisciplinary
approach, combining pharmacological interventions with physical
or cognitive interventions, is advocated for severe forms of
FMS (Macfarlane 2017; Petzke 2017). Reasons for preferring
non-pharmacological therapies as first line therapies include
non-pharmacological therapies having more ubiquitous clinically
relevant eMects on FMS symptom domains - pain, sleep
disturbance, fatigue, aMective symptoms (depression/anxiety),
functional deficit and cognitive impairment - and less side eMects
than medications (Perrot 2014). Positive, yet declining eMects
of non-pharmacological therapies such as cognitive-behavioral
therapies (Bernardy 2018), and multicomponent treatments
(Arnold 2012), could be demonstrated in follow-ups aTer the end of
treatment.
Conventional analgesics are usually not eMective. Treatment is
oTen by so-called pain modulators, such as antidepressants like
duloxetine and amitriptyline (Häuser 2013; Lunn 2014; Moore
2012a), or antiepileptics like gabapentin or pregabalin (Cooper
2017; Moore 2009; Üceyler 2013, WiMen 2013). The proportion of
people who achieve worthwhile pain relief even with eMective
interventions (typically at least a 50% reduction in pain intensity;
Moore 2013a), is small, generally only 10% to 15% more than with
placebo, with number needed to treat for an additional beneficial
outcome (NNTB) usually between 6 and 14 (WiMen 2013). Those
who do experience good levels of pain relief with pregabalin also
benefit from substantial improvements in other symptoms, such
as fatigue, function, sleep, depression, anxiety, and ability to work,
with significant improvement in quality of life (Moore 2010b; Moore
2014a; Straube 2011). Fibromyalgia is similar to other chronic pain
conditions in that only a small proportion of trial participants have
a good response to treatment (Moore 2013b).
Description of the interventions
The exact number and types of pharmacological therapies that
might be used for the treatment of fibromyalgia is not known.
Medicines from a number of diMerent classes have been used
to treat fibromyalgia in clinical practice, and trials and Cochrane
Reviews of eMicacy are likely to be found covering the following
drug classes:
1. antidepressants (e.g. amitriptyline or other tricyclic
antidepressants, duloxetine, milnacipran, mirtazapine);
2. antiepileptics (e.g. gabapentin, pregabalin, topiramate);
3. antipsychotics (e.g. quetiapine);
4. cannabinoids (e.g. nabilone);
5. nonsteroidal anti-inflammatory medicines (NSAIDs, e.g.
diclofenac, ibuprofen, naproxen);
6. opioids (e.g. morphine, oxycodone, tramadol).
It is also possible, or even likely, that other pharmacological
therapies outside these classes have been tested, and reviews
may be available. For the purposes of this overview, we define
pharmacological as relating to the use and eMects of medicines, and
define medicines or medicine as a defined or undefined chemical
that is ingested or otherwise introduced into the body.
How the intervention might work
Because of the large range of medicines that might possibly be
found for this overview, and because diMerent medicines within a
particular class can have diMerent modes of action, no meaningful
discussion of how interventions might work is possible here,
especially give the unknown aetiology of FMS. As this overview
will concentrate on Cochrane Reviews, and each will have its own
section on how that particular intervention works, readers are
directed to those sections of the individual reviews.
Why it is important to do this overview
The standards used to assess evidence in chronic pain trials have
changed substantially, with particular attention being paid to
trial duration, withdrawals, and statistical imputation following
withdrawal, all of which can substantially alter estimates of
eMicacy. The most important change is the move from using
average pain scores, or average change in pain scores, to the
number of people who have a large decrease in pain (by at least
50%) and who continue in treatment, ideally in trials of 8 to 12
weeks or longer. Pain intensity reduction of 50% or more has been
shown to correlate with improvements in comorbid symptoms,
function, and quality of life for people with chronic pain (Conaghan
2015; Moore 2013a; Peloso 2016), and specifically fibromyalgia
(Moore 2010b; Straube 2011).
There is now increasing recognition that results based on a small
number of small underpowered studies may well give an incorrect
or highly imprecise answer to a clinical question. Many studies in
chronic pain have historically been relatively small, and analysis
of smaller trials in Cochrane Reviews has been criticised (AlBalawi
2013; Roberts 2015). An analysis on the impact of study size in
Cochrane Reviews has highlighted this issue, and pointed out that
if two adequately powered studies are available, then omitting all
underpowered studies makes little or no diMerence to the result
(Turner 2013). The standard Cochrane 'Risk of bias' assessment
does not include size, unless added by authors. Some items, like
inconsistency or heterogeneity may be a consequence of small size
(IntHout 2015; Turner 2013), but in any event, simulation studies
demonstrate that the chances of heterogeneity tests accurately
detecting true homogeneity or heterogeneity with a small number
of small studies is almost random (Gavaghan 2000). Alternative
approaches not available in Review Manager 5 soTware (Review
Manager 2020), may oMer a way forward in some circumstances
(Kulinskaya 2015). There are potentially large eMects of random
chance when the numbers of events are small (Flather 1997; Moore
1998; Pogue 1997; Pogue 1998). A simulation exercise suggests
that, in most circumstances, a minimum data requirement is 250
to 500 events, such as a participant achieving adequate pain relief
(Thorlund 2011).
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A 1996 survey indicated that 90% of meta-analyses of analgesic
interventions had methodological flaws that could limit their
validity, and that meta-analyses of low quality produced
significantly more positive conclusions (Jadad 1996a). Even in good
quality Cochrane Reviews, the use of Grading of Recommendations
Assessment, Development and Evaluation (GRADE) to summarise
the certainty of evidence indicates that fewer than 20% of reviews
actually have any high quality evidence (Fleming 2016). Judging
systematic review quality is diMicult. AMSTAR (A MeaSurement Tool
to Assess systematic Reviews) is most oTen used, and a newer
version now exists in AMSTAR-2 (Shea 2017). This is a generic
tool examining what is regarded as best practice in systematic
review methodology, and its use in back pain indicated that 86% of
systematic reviews provided low or critically low confidence in their
results in cannabis-based medicine reviews for pain (Moore 2020),
90% in exercise therapy for low back pain (Almeida 2020), 99%
in bariatrics (Storman 2020), and 100% in spine surgery (Dettori
2020). Cochrane Reviews rated mainly moderate or high confidence
(Almeida 2020; Moore 2020).
Beyond the generic, there are also specific criteria important to
pain studies, including adequate initial pain for a sensitive assay
(Moore 2010a), the importance of patient centred outcomes (Moore
2013a), underestimation of pain by professionals when compared
with patients (Seers 2018), and the importance of imputation
method in some circumstances (Moore 2012b). These methods
have been used for judging the quality of systematic reviews of
cannabis-based medicines (Moore 2020).
This overview will examine how Cochrane Reviews of fibromyalgia
meet these criteria as well as summarising the current available
knowledge. It aims to set high standards and mark a departure
from how overview reviews were conducted previously, and inform
on how reporting of Cochrane Reviews on fibromyalgia may be
improved.
O B J E C T I V E S
To provide an overview of the therapeutic eMicacy
of pharmacological therapies for fibromyalgia (fibromyalgia
syndrome) in adults, and to report on adverse events associated
with their use. The major comparison of interest will be with
placebo.
M E T H O D S
Criteria for considering reviews for inclusion
We will include all Cochrane Reviews of pharmacological therapies
for the treatment of fibromyalgia in adults. These are likely to
involve only randomised, controlled double-blind trials (RCTs), but
we will also include those examining non-randomised studies.
Search methods for identification of reviews
We will search the most recent issue of the Cochrane Database of
Systematic Reviews (via the Cochrane Library). The search strategy
is presented in Appendix 2.
Data collection and analysis
Two review authors will independently select reviews for inclusion,
carry out assessments of methodological quality, extract data,
analyse data if required, assess how the review authors have
used the GRADE criteria and make their own GRADE assessments
based on the information provided. Because some of the overview
authors are also authors of Cochrane Reviews likely to be included
in the overview, care will be taken that any final decisions on any
assessments are made by non-conflicted authors of that review.
Final assessments will require the agreement of all authors.
Selection of reviews
Included reviews will assess RCTs or non-randomised studies
evaluating the eMects of any pharmacological intervention given
for relief of fibromyalgia pain, compared with placebo or a diMerent
active treatment, and provide:
1. details of inclusion and exclusion criteria;
2. details of databases searched and relevant search strategies;
3. patient-reported pain relief; and
4. summary results for at least one desired outcome.
Data extraction and management
We will extract data in the included reviews using a standard piloted
data extraction form, using original study reports only if specific
data are missing.
We will collect information on:
1. number of included studies and participants;
2. drug, dose, and route of administration;
3. baseline demographic measures, pain, and other measures;
4. any additional methodological information that may be of
importance.
We will extract information from randomised studies on risk
diMerence (RD), or risk ratio (RR), and number needed to treat
for an additional beneficial outcome (NNTB), number needed to
treat to prevent an event (NNTp), and number needed to treat for
an additional harmful outcome (NNTH), or calculate these from
available data.
We anticipate that reviews may use a variety of outcome measures,
with the majority using standard subjective scales (numerical rating
scale or visual analogue scale) for pain intensity or pain relief, or
both. We are particularly interested in the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
definitions for moderate and substantial benefit in chronic pain
studies (Dworkin 2008).
These are defined as at least 30% pain relief over baseline
(moderate), at least 50% pain relief over baseline (substantial),
much or very much improved on Patient Global Impression of
Change (PGIC), (moderate), and very much improved on PGIC
(substantial). These dichotomous outcomes should be used where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50%, and with pain not worse than mild (Moore 2013a;
O'Brien 2010).
As FMS is a long lasting condition, we will seek outcomes as close
as possible to three months (13 weeks) aTer treatment, the most
commonly used duration of clinical trials. We will not use outcomes
earlier than one month (four weeks).
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Primary outcomes
1. Participant-reported pain relief of 50% or greater (substantial
improvement)
2. PGIC very much improved (substantial improvement)
3. Safety: participants experiencing any serious adverse event.
Serious adverse events typically include any untoward medical
occurrence or eMect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability
or incapacity, is a congenital anomaly or birth defect, is an
'important medical event' that may jeopardise the person,
or may require an intervention to prevent one of the above
characteristics or consequences
4. Tolerability: withdrawals due to adverse events
Secondary outcomes
1. Participant-reported pain relief of 30% or greater (moderate
improvement)
2. PGIC much or very much improved (moderate improvement)
3. Participant-reported sleep problems (continuous outcome: we
will prefer composite measures over single item scales)
4. Participant-reported fatigue (continuous outcome: we will
prefer composite measures over single item scales)
5. Participant-reported mean pain intensity (continuous outcome:
we will prefer change from baseline scores over intensity at the
end of the study)
6. Participant-reported health-related quality of life (we will prefer
disease-specific instruments such as the Fibromyalgia Impact
Questionnaire (FIQ) over generic instruments. If FIQ scores are
reported we will calculate the number of participants with a
clinically-relevant improvement of 20% or greater
7. Participant-reported negative mood (continuous outcome: we
will prefer composite measures such as the Beck Depression
Inventory (BDI) or the Hospital Anxiety and Depression (HAD)
scale over single item scales)
8. Withdrawals due to lack of eMicacy
9. Participants with any adverse event
10.Participants with specific adverse events: somnolence;
substantial weight gain; elevated liver enzymes are examples
Assessment of methodological quality of included reviews
Assessment of review quality will be made by a minimum of two
authors, with discussion with other authors where necessary to
make a consensus determination.
We will assess each included review to determine if it satisfies the
criteria specified in the AMSTAR 2 tool for rigorous methodological
certainty (Shea 2017). We will also conduct additional validity
checks of potential critical importance in the evaluation of
analgesic eMicacy (Moore 2020). These will include the following.
• Were included studies both randomised and double blind
(Jadad 1996b)?
• Did the review use defined diagnostic criteria for fibromyalgia?
• Did the reviews include only studies in which patients made
their own assessment of pain? (Professional and patient
assessment oTen disagrees, with professionals significantly
underestimating pain (Seers 2018).)
• Did the reviews use studies with defined minimum pain intensity
of moderate or severe pain? (Mild pain can reduce the sensitivity
of trials to demonstrate an analgesic eMect (Moore 2010a).)
• Did the reviews examine study size as a confounding factor
in any analysis of eMicacy? (Systematic reviews have been
criticised for being over-confident of results with inadequate
data (AlBalawi 2013; Roberts 2015; Turner 2013); there is
increasing evidence of the importance of small trial size, both
because of random chance [16,52,76], and as an important
source of bias (Dechartres 2013; Dechartres 2014; IntHout 2015;
Nüesch 2010).)
• Did the review examine susceptibility to publication bias?
• Did the reviews examine or comment upon imputation methods
for missing data as potential source of bias?
We will also investigate two additional criteria not covered by these
criteria; these are:
• did the reviews analyse the inclusion and exclusion criteria of
the studies and discuss the utility of the study results to the
people with fibromyalgia in routine clinical care?
• did the reviews analyse if the studies analysed the impact of the
use of rescue medication on study findings?
For each review, we will assess the susceptibility to publication bias
by calculating the number of participants in studies with zero eMect
(RR = 1) that would be needed to give an NNTB too high to be
clinically relevant (Moore 2008). In this case, we will use as a cut-
oM for clinical relevance, NNTB values of 10 and 20 for the outcome
of participant reported pain relief of 30% or greater, or 50% or
greater. We use this method because statistical tests for presence of
publication bias have been shown to be unhelpful (Thornton 2000).
Data synthesis
We will use information on the selected eMicacy outcomes to draw
up comparisons of analgesic eMicacy, using indirect comparisons of
diMerent medicines from almost identical clinical trial conditions,
with placebo as a common comparator (Glenny 2005; Song 2003).
It is known that direct comparison studies are almost completely
absent, and probably too small to be of value, but we will note
where they impart useful observations.
If the selected eMicacy outcomes are not provided in an individual
review, wherever possible we will calculate them from the data
provided. We plan no further data synthesis. In this unlikely event,
outcome data for at least 200 participants will have to be available
for any outcome (Moore 1998). Where appropriate we will use or
calculate risk ratio (RR) or risk diMerence (RD) with 95% confidence
intervals (CIs) using a fixed-eMect model (Morris 1995). We will use
or calculate NNTB and NNTH with 95% CIs using the pooled number
of events, using the method devised by Cook and Sackett (Cook
1995). We will assume a statistically significant diMerence from
control when the 95% CI of the RR does not include the number one
or for the RD the number zero.
Summary of findings and assessment of the certainty of the
evidence
We will use the GRADE system to assess the certainty of the
evidence related to the key outcomes listed in 'Types of outcome
measures', as appropriate (Appendix 3). Two review authors will
independently rate the certainty of each outcome independently of
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any GRADE evaluation in the original reports. We will pay particular
attention to how the review authors have used GRADE criteria.
We will pay particular attention to inconsistency, where point
estimates vary widely across studies, or CIs of studies showing
minimal or no overlap (Guyatt 2011). Small studies have been
shown to overestimate treatment eMects, probably because the
conduct of small studies is more likely to be less rigorous, allowing
critical criteria to be compromised (Dechartres 2013; Nüesch 2010),
and large studies oTen have smaller treatment eMects (Dechartres
2014).
In addition, there may be circumstances where the overall rating
for a particular outcome needs to be adjusted as recommended by
GRADE guidelines (Guyatt 2013a; Schünemann 2021). For example,
if there are so few data that the results are highly susceptible to the
random play of chance, or if studies use last observation carried
forward (LOCF) imputation in circumstances where there are
substantial diMerences in adverse event withdrawals, one would
have no confidence in the result, and would need to downgrade the
certainty of the evidence by three levels, to very low certainty. In
circumstances where there are no data reported for an outcome,
we will report the level of evidence as very low certainty (Guyatt
2013b).
We will use the following descriptors for levels of evidence (EPOC
2015); substantially diMerent in this context implies a large enough
diMerence that it might aMect a decision.
1. High: this research provides a very good indication of the
likely eMect. The likelihood that the eMect will be substantially
diMerent is low.
2. Moderate: this research provides a good indication of the
likely eMect. The likelihood that the eMect will be substantially
diMerent is moderate.
3. Low: this research provides some indication of the likely eMect.
However, the likelihood that it will be substantially diMerent is
high.
4. Very low: this research does not provide a reliable indication
of the likely eMect. The likelihood that the eMect will be
substantially diMerent is very high.
We will use the amount and certainty of evidence to report results
in a hierarchical way, as has been done previously (Moore 2015;
WiMen 2017). We will split the available information into five groups,
essentially according to the GRADE descriptors.
1. Medicines and doses for which Cochrane Reviews found no
information (very low-certainty evidence).
2. Medicines and doses for which Cochrane Reviews found
inadequate information: fewer than 200 participants in
comparisons, in at least two studies (very low-certainty evidence
in the review).
3. Medicines and doses for which Cochrane Reviews found
evidence of eMect, but where results were potentially subject
to publication bias. We will consider the number of additional
participants needed in studies with zero eMect (relative benefit
of one) required to change the NNTB for at least 50% maximum
pain relief to an unacceptably high level (in this case the
arbitrary NNTB of 10) (Moore 2008). Where this number is less
than 400 (equivalent to four studies with 100 participants per
comparison, or 50 participants per group), we will consider
the results to be susceptible to publication bias and therefore
unreliable (low-certainty evidence).
4. Medicines and doses for which Cochrane Reviews found no
evidence of eMect or evidence of no eMect: more than 200
participants in comparisons, but where there was no statistically
significant diMerence from placebo (moderate- or high-certainty
evidence).
5. Medicines and doses for which Cochrane Reviews found
evidence of clinically relevant eMect, where results were reliable
and not subject to potential publication bias (high-certainty
evidence).
'Summary of findings' tables
We will consider creating 'Summary of findings' tables for seven
outcomes, if the data allow, and it is considered appropriate
(Pollock 2021). The proposed template is in Appendix 4.
A C K N O W L E D G E M E N T S
Cochrane Review Group funding acknowledgement: this project
was funded by the National Institute for Health Research (NIHR)
via Cochrane Infrastructure funding to the Cochrane Pain, Palliative
and Supportive Care Review Group (PaPaS). The views expressed
are those of the author(s) and not necessarily those of the NIHR or
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A P P E N D I C E S
Appendix 1. Methodological considerations for chronic pain
There have been several recent changes in how the eMicacy of conventional and unconventional treatments is assessed in chronic painful
conditions. The outcomes are now better defined, particularly with new criteria for what constitutes moderate or substantial benefit
(Dworkin 2008); older trials may only report participants with 'any improvement'. Newer trials tend to be larger, avoiding problems from
the random play of chance. Newer trials also tend to be of longer duration, up to 12 weeks, and longer trials provide a more rigorous and
valid assessment of eMicacy in chronic conditions. New standards have evolved for assessing eMicacy in neuropathic pain, and we are now
applying stricter criteria for the inclusion of trials and assessment of outcomes, and are more aware of problems that may aMect our overall
assessment. To summarise some of the recent insights that must be considered in this new review:
1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore 2011a; Moore
2011b), back pain (Moore 2010d), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases average results
usually describe the experience of almost no-one in the trial. Data expressed as averages are potentially misleading, unless they can
be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the individual either has or does not have the outcome) usually from
pain changes or patient global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In arthritis, trials of less
than 12 weeks' duration, and especially those shorter than eight weeks, overestimate the eMect of treatment (Moore 2010c); the eMect
is particularly strong for less eMective analgesics,
3. The proportion of patients with at least moderate benefit can be small, even with an eMective medicine, falling from 60% with an
eMective medicine in arthritis to 30% in fibromyalgia (Moore 2009; Moore 2010c; Moore 2013b; Moore 2014b; Straube 2008). A Cochrane
Review of pregabalin in neuropathic pain and fibromyalgia demonstrated diMerent response rates for diMerent types of chronic pain
(higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia) (Moore 2009).
4. Individual patient analyses of pregabalin studies in fibromyalgia indicate that patients who get good pain relief (moderate or better),
have major benefits in many other outcomes, aMecting quality of life in a significant way (Moore 2010b; Moore 2014a).
5. Imputation methods such as last observation carried forward (LOCF), used when participants withdraw from clinical trials, can overstate
drug eMicacy especially when adverse event withdrawals with drug are greater than those with placebo (Moore 2012b).
Appendix 2. Search strategy
#1 MeSH descriptor: [Fibromyalgia] explode all trees and with qualifier(s): [Drug therapy - DT]
#2 "fibromyalgia":ti (Word variations have been searched)
#3 #1 or #2
Appendix 3. GRADE: criteria for assigning grade of evidence
The GRADE system uses the following criteria for assigning a quality level to a body of evidence (Schünemann 2021).
1. High: randomised trials; or double-upgraded observational studies
2. Moderate: downgraded randomised trials; or upgraded observational studies
3. Low: double-downgraded randomised trials; or observational studies
4. Very low: triple-downgraded randomised trials; or downgraded observational studies; or case series/case reports
Factors that may decrease the quality level of a body of evidence are:
1. limitations in the design and implementation of available studies suggesting high likelihood of bias;
2. indirectness of evidence (indirect population, intervention, control, outcomes);
3. unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses);
4. imprecision of results (wide confidence intervals);
5. high probability of publication bias.
Factors that may increase the quality level of a body of evidence are:
1. large magnitude of eMect;
2. all plausible confounding would reduce a demonstrated eMect or suggest a spurious eMect when results show no eMect;
3. dose-response gradient.
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Appendix 4. Template Summary of Findings table
 



















Pain relief of 50% or more            
PGIC very much improved            
Serious adverse events            
Withdrawals due to adverse events            
Pain relief of 30% or more            
PGIC much or very much improved            
Withdrawal due to lack of efficacy            
 
 
W H A T ' S   N E W
 
Date Event Description
13 August 2021 New citation required but no major
changes
Addition of AMSTAR-2 and pain critical items to evaluations of re-
views to be included in this overview.
New author team to align with parallel overview review on non-
pharmacological interventions.
Minor changes in text to bring the protocol in line with current
standards and to update with more recent relevant publications.
Title updated to include 'fibromyalgia syndrome'.
 
H I S T O R Y
Protocol first published: Issue 10, 2018
C O N T R I B U T I O N S   O F   A U T H O R S
RAM, WH, and EF draTed the amended protocol. All authors had input into the protocol development and agreed the final version. RAM
is the guarantor.
D E C L A R A T I O N S   O F   I N T E R E S T
RAM: none known; RAM is an author of several Cochrane Reviews of pharmacological interventions for FMS, and in 2021 RAM received an
honorarium from Biogen for advice relating to possible future design of randomised trials in diabetic neuropathy.
EF: none known.
WH: none known. WH is a specialist in general internal medicine, psychosomatic medicine and pain medicine, who treats people with FMS.
He is a member of the medical board of the German Fibromyalgia Association and of the European Network of Fibromyalgia Associations.
He is aMiliated with the German Pain Society and is the head of the steering committee of the guideline on FMS of the Association
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of the Scientific Medical Societies in Germany. He is member of the steering committee of the European League Against Rheumatism
(EULAR) update recommendations on the management of fibromyalgia. He receives royalties from Hypnos Publishers for a CD with
medical hypnosis for FMS. He has published systematic reviews and opinions on fibromyalgia pharmacological and non-pharmacological
treatment.
RFB: none known.
SP: none known; SP is a specialist in rheumatology and pain medicine, who treats people with FMS. He is a member of the steering
committee of the European League Against Rheumatism (EULAR) update recommendations on the management of fibromyalgia. SP has
published opinions on fibromyalgia treatment, and is aMiliated to the Société Française d'Etude et de Traitement de la Douleur (French
Society on Pain; SFTED) that has published recommendations on the treatment of fibromyalgia.
JB: none known.
SM: none known.
SS: none known; SS is a specialist occupational medicine physician and some of the patients he assesses have chronic painful conditions
including fibromyalgia.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support provided
External sources
• National Institute for Health Research (NIHR), UK
Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS)
Pharmacological therapies for fibromyalgia (fibromyalgia syndrome) in adults - an overview of Cochrane Reviews (Protocol)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
